STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $54,222 | -99.1% | 13,762 | -97.6% | 0.00% | -100.0% |
Q2 2023 | $6,064,532 | +1.6% | 570,511 | -20.4% | 0.00% | 0.0% |
Q1 2023 | $5,971,919 | -13.5% | 716,917 | -4.1% | 0.00% | -25.0% |
Q4 2022 | $6,902,065 | -31.7% | 747,786 | -5.0% | 0.00% | -33.3% |
Q3 2022 | $10,104,000 | -3.0% | 786,885 | -0.2% | 0.01% | 0.0% |
Q2 2022 | $10,415,000 | +82.0% | 788,381 | +190.0% | 0.01% | +100.0% |
Q1 2022 | $5,723,000 | +880.0% | 271,886 | +1017.4% | 0.00% | – |
Q4 2021 | $584,000 | -15.7% | 24,331 | -10.5% | 0.00% | – |
Q3 2021 | $693,000 | +63.8% | 27,195 | +116.4% | 0.00% | – |
Q2 2021 | $423,000 | +20.2% | 12,567 | +38.6% | 0.00% | – |
Q1 2021 | $352,000 | -38.2% | 9,068 | -1.5% | 0.00% | – |
Q4 2020 | $570,000 | +153.3% | 9,209 | +36.7% | 0.00% | – |
Q3 2020 | $225,000 | +54.1% | 6,735 | +9.6% | 0.00% | – |
Q2 2020 | $146,000 | +8.1% | 6,145 | +4.0% | 0.00% | – |
Q1 2020 | $135,000 | +48.4% | 5,910 | +81.8% | 0.00% | – |
Q4 2019 | $91,000 | +54.2% | 3,251 | +15.1% | 0.00% | – |
Q3 2019 | $59,000 | – | 2,825 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 17,161,713 | $1,062,825,000 | 82.06% |
RTW INVESTMENTS, LP | 3,544,248 | $219,495,000 | 3.68% |
Cormorant Asset Management, LP | 1,437,807 | $89,043,000 | 2.12% |
Redmile Group, LLC | 2,686,234 | $166,358,000 | 2.01% |
ACUTA CAPITAL PARTNERS, LLC | 92,500 | $5,729,000 | 1.56% |
Pinz Capital Management, LP | 34,200 | $2,118,000 | 0.96% |
Birchview Capital, LP | 20,000 | $1,239,000 | 0.71% |
HighVista Strategies LLC | 17,668 | $1,094,000 | 0.70% |
GILDER GAGNON HOWE & CO LLC | 1,470,841 | $91,089,000 | 0.45% |
Perceptive Advisors | 671,978 | $41,616,000 | 0.45% |